Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Novo Nordisk A/S (NYSE: NVO) is one of the top cheap pharmaceutical stocks to buy now. On August 1, Bernstein analyst Florent ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...

Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over ...